



REMISSION OR SUPER RESPONDER

SPECIAL TWO PART SERIES

Reference list for ADVENT Interactive Clinical Tutorial held on 24 August 2023

1. Abatacept Public Summary Document. November 2007. [Click to access](#). Accessed August 2023.
2. Aletaha D, et al. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320(13):1360-1372. [PMID: 30285183]
3. Anderson JK, et al. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S14-36. [PMID: 22588741]
4. Denton E, et al. Biologic Responders and Super-responders in the International Severe Asthma Registry. Am J Respir Crit Care Med. 2023;207:A4753. [Click to access](#). Accessed August 2023.
5. Eger K, et al. J Allergy Clin Immunol Pract. Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation. 2021;9(3):1194-200. [PMID: 33069885]
6. Fletcher A et al. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Rheumatology (Oxford). 2022;61:3939-3951. [Click to access](#). Accessed August 2023.
7. Gibson PG, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Int Med J. 2016;46(9):1054-62. [PMID: 27350385]
8. Harvey ES, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5). [PMID: 32139455]
9. Hiles SA, et al. Treatable Traits That Predict Health Status and Treatment Response in Airway Disease. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1255-1264.e2. [PMID: 33039647]
10. Julia A, et al. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy. BMC Musculoskelet Disord. 2021;22:372. [Click to access](#). Accessed August 2023.
11. Kekow J, et al. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNF α blocker failure. Biologics. 2012;6:191-9. [PMID: 22848150]
12. Kida D, et al. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients. Sci Rep. 2020;10:19717. [Click to access](#). Accessed August 2023.
13. McDonald, VM et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019 Jan;24(1):37-47. [PMID: 30230137]
14. Milger K, et al. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort. J Allergy Clin Immunol Pract. 2023;S2213-2198(23)00646-3. [Click to access](#). Accessed August 2023.
15. Ogdie A, et al. Measuring Outcomes in Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2020;72(Suppl 10):82-109. [PMID: 33091263]
16. Salaffi F, et al. Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis. Health Qual Life Outcomes. 2014;12:129 [Click to access](#). Accessed August 2023.
17. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. [PMID: 36357155]
18. Smolen JS, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6-16. [PMID 23749611]
19. Sposato B, et al. Clinical Asthma Remission Obtained with Biologics in Real Life: Patients' Prevalence and Characteristics. J Pers Med. 2023;13(6):1020. [Click to access](#). Accessed August 2023.
20. van der Heijde D, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978-991. [PMID 28087505]
21. Westerhof GA, et al. Clinical predictors of remission and persistence of adult-onset asthma. J Allergy Clin Immunol. 2018;141(1):104-9.e3. [PMID: 28438546]
22. Wysocki T, et al. Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to Clinical Practice Cells. 2020;9:1127. [PMID: 32370106]